Chart-Typ:
Zeitraum:
| JEFFERIES stuft STMicro auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für STMicroelectronics anlässlich einer Investorenveranstaltung auf "Buy" mit einem Kursziel von 30 Euro belassen. Der Chef... ► Artikel lesen |
| CAC 40 Up 0.5%; STMicroElectronics Rises Over 7% | BRUSSELS (dpa-AFX) - Despite lingering concerns about trade tensions, French stocks are gaining some ground in positive territory on Wednesday with investors expecting an interest rate cut from... ► Artikel lesen |
| Aktien Europa: EuroStoxx am Tag vor EZB-Entscheid weiter aufwärts | PARIS/LONDON/ZÜRICH (dpa-AFX) - An den europäischen Börsen ist am Mittwoch die Risikobereitschaft der Anleger wieder gestiegen. Der EuroStoxx 50 legte gegen Mittag um 0,55 Prozent auf 5.405 Punkte... ► Artikel lesen |
| VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen |
| Organovo, Inc.: Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements | SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches... ► Artikel lesen |
| Organovo, Inc.: Organovo Provides Business Update | SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches... ► Artikel lesen |
| INOVIO Pharmaceuticals, Inc.: INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights |
On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen |
| INOVIO Pharmaceuticals, Inc.: INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights | Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen |
| Inovio Pharmaceuticals Inc. Q4 Income Declines | WASHINGTON (dpa-AFX) - Inovio Pharmaceuticals Inc. (INO) released a profit for fourth quarter that decreased from last yearThe company's bottom line came in at $19.4 million, or $0.65 per share.... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu STARDUST POWER INC finden Sie auf Wallstreet Online.